PARTNER CONTENT PROVIDED BY ALZHEON, INC.

Preserving Future Memories

Alzheon is poised to introduce the first oral treatment that can slow or stop Alzheimer's disease.

Part 1: The Role of APOE Genotyping in Alzheimer's Disease Risk Stratification

Marwan Sabbagh, MD
by Marwan Sabbagh, MD

Dr. Marwan Sabbagh has more than 25 years of experience in treating patients with progressive forms of dementia. In our timely interview, he discusses how genetic testing, specifically APOE genotyping, can help diagnosis and assess risk stratification of Alzheimer's disease.

Historically, genetic testing has not been routine in clinical practice, but recent studies have shown that disclosing genetic information, such as APOE status, is a safe way to assess a patient’s risk for the progression of dementia. Watch now to learn how new tests and treatments may lead to increased use of APOE genotyping for Alzheimer’s disease risk stratification.

Check out Part 2 of Dr. Sabbagh's interview by clicking here!